

PARLIAMENTARY INQUIRY QUESTION ON NOTICE

Department of Health Disability and Ageing

Select Committee on PFAS (per and polyfluoroalkyl substances)

Inquiry into the extent, regulation and management of PFAS

10 June 2025

PDR Number: IQ25-000037

Potential public health risk of fluorinated pharmaceuticals that meet the OECD definition of PFAS

Written

Senator: Lidia Thorpe

Question:

11. How is the Department addressing the potential public health risk of fluorinated pharmaceuticals that meet the OECD definition of PFAS?

Answer:

- The Therapeutic Goods Administration evaluates the safety, quality and efficacy of prescription medicines before they are approved for registration in the Australian Register of Therapeutic Goods. These evaluations include consideration by chemists, biochemists, microbiologists, toxicologists and other experts, including relevant data on the therapeutic effectiveness of the medicine.